摘要
心力衰竭是各种心脏疾病的终末期表现,心力衰竭患者住院率高且预后不良。近五十年来,心力衰竭的诊断和治疗方式在不断改变。本文回顾了心力衰竭分期、慢性心力衰竭命名与分类以及心力衰竭治疗药物、治疗策略的改变。并对目前新型的抗心力衰竭药物如血管紧张素受体脑啡肽酶抑制剂(ARNI)、钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)、可溶性鸟苷酸环化酶刺激剂(维立西呱)做了详细介绍。总之,本文通过对心力衰竭的研究进展作一述评,旨在为临床医师提供参考。
Heart failure is the end-stage manifestation of cardiac diseases with a high hospitalization rate and poor prognosis.In the past 50 years,heart failure diagnosis and management are constantly changing.This article reviews chronic heart failure staging,nomenclature and classification,and also changes in drugs and treatment strategies.Moreover,a new class of drugs,such as ARNI,SGLT2i,and vericiguat will be introduced in detail.
作者
罗素新
LUO Suxin(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《西部医学》
2023年第3期313-317,共5页
Medical Journal of West China
基金
重庆市卫健委适宜卫生技术推广项目(2020jstg023)。
关键词
心力衰竭
诊断
药物疗法
研究进展
Heart failure
Diagnosis
Pharmacologic treatment
Research progress
